Clene presents preclinical data supporting CNM-Au8 for Parkinson’s disease

Clene (CLNN) and its wholly owned subsidiary Clene Nanomedicine announced new preclinical data showing that CNM-Au8 improved key measures of cellular health in a novel dopaminergic neuron model of Parkinson’s disease. The study results will be presented today at the Michael J. Fox Foundation H2 Therapeutics Stewardship Meeting in New York City by Associate Professor Jerome Mertens. The study used skin cells from 8 sporadic PD patients, 14 familial PD patients-13 with LRRK2 gene mutations and 1 with a PARK gene mutation-and 13 healthy individuals. The skin cells were directly converted into dopaminergic neurons, the brain cells essential for movement and the most vulnerable to degeneration in PD. This innovative method retains age-related characteristics from PD patient donors, enabling researchers to study disease processes as they occur in aged disease-relevant neurons. Key findings from CNM-Au8 treatment include: Improved mitochondrial health in familial PD; Reduced inflammation in sporadic PD; Restored cellular metabolism; Normalized dysregulated gene expression; Favorable safety profile.